{"transactions":[{"id":721393,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:57:48.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":5407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":81093,"derivative":{"exercise_price":13.41,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":5407},"source":{"system":"sec-edgar","filing":"0001193125-26-292767","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526292767/ownership.xml","form_type":"4"}},{"id":721392,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:57:48.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":5407,"price":24.5,"value":132471.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":60612,"source":{"system":"sec-edgar","filing":"0001193125-26-292767","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526292767/ownership.xml","form_type":"4"}},{"id":721391,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:57:48.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":5407,"price":13.41,"value":72507.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 620 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 30, 2026."}],"balance_after":66019,"source":{"system":"sec-edgar","filing":"0001193125-26-292767","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526292767/ownership.xml","form_type":"4"}},{"id":722910,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T20:05:37.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":60000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-290486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526290486/ownership.xml","form_type":"4"}},{"id":722909,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:05:37.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":22.95,"value":137700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":59992,"source":{"system":"sec-edgar","filing":"0001193125-26-290486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526290486/ownership.xml","form_type":"4"}},{"id":722908,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:05:37.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":7.56,"value":45360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":65992,"source":{"system":"sec-edgar","filing":"0001193125-26-290486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526290486/ownership.xml","form_type":"4"}},{"id":726550,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":66000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726549,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":96000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726548,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":21.4227,"value":642681.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":59992,"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726547,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":7.56,"value":226800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":89992,"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726546,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":11845,"price":20.2214,"value":239522.483,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":59992,"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726545,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":7.56,"value":45360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":71837,"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":885228,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-24T21:05:11.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":9189,"price":19.4973,"value":179160.6897,"ownership":{"direct":true},"balance_after":65837,"source":{"system":"sec-edgar","filing":"0001193125-26-066955","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526066955/ownership.xml","form_type":"4"}},{"id":951880,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:04:31.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":139000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":139000,"derivative":{"exercise_price":15.31,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":139000},"source":{"system":"sec-edgar","filing":"0001193125-26-002386","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526002386/ownership.xml","form_type":"4"}},{"id":951879,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:31.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":3155,"price":15.17,"value":47861.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":75026,"source":{"system":"sec-edgar","filing":"0001193125-26-002386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526002386/ownership.xml","form_type":"4"}},{"id":951878,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:31.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,992 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on December 31, 2025."}],"balance_after":78181,"source":{"system":"sec-edgar","filing":"0001193125-26-002386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526002386/ownership.xml","form_type":"4"}},{"id":1311018,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T21:15:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":161000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":161000,"derivative":{"exercise_price":7.11,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":161000},"source":{"system":"sec-edgar","filing":"0000950170-25-002102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000095017025002102/ownership.xml","form_type":"4"}},{"id":1311017,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:15:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":36000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,937 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 28, 2024."}],"balance_after":45189,"source":{"system":"sec-edgar","filing":"0000950170-25-002102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000095017025002102/ownership.xml","form_type":"4"}},{"id":1407777,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T20:30:03.000Z","date":"2024-09-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 3, 2022, the Reporting Person was granted an option to purchase 30,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On September 13, 2024, the performance criteria underlying such shares were met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest in full on March 13, 2026, subject to the Reporting Person's continued service on such date."}],"balance_after":30000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-106387","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000095017024106387/ownership.xml","form_type":"4"}},{"id":1688284,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T21:15:21.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":121000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":121000,"derivative":{"exercise_price":5.71,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":121000},"source":{"system":"sec-edgar","filing":"0001209191-24-000764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000120919124000764/doc4.xml","form_type":"4"}},{"id":2068496,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T21:30:34.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":135000,"derivative":{"exercise_price":7.78,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-23-000948","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000120919123000948/doc4.xml","form_type":"4"}},{"id":2081964,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-19T21:42:27.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 3, 2022, the Reporting Person was granted an option to purchase 36,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On December 15, 2022, the performance criteria underlying such shares were met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest in full on June 15, 2024, subject to the Reporting Person's continued service on such date."}],"balance_after":36000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-02","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-22-061947","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000120919122061947/doc4.xml","form_type":"4"}},{"id":2128612,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-01T20:30:31.000Z","date":"2022-10-31","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 3, 2022, the Reporting Person was granted an option to purchase 36,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On October 31, 2022, the performance criteria underlying such shares were met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest in full on April 30, 2024, subject to the Reporting Person's continued service on such date."}],"balance_after":36000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-02","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-22-055037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000120919122055037/doc4.xml","form_type":"4"}},{"id":2361325,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-02T23:46:58.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":86500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":86500,"derivative":{"exercise_price":13.41,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":86500},"source":{"system":"sec-edgar","filing":"0000899243-22-008706","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000089924322008706/doc4.xml","form_type":"4"}},{"id":2655032,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-25T21:00:45.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":387069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on June 1, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":387069,"derivative":{"exercise_price":19,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":387069},"source":{"system":"sec-edgar","filing":"0000899243-21-025979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000089924321025979/doc4.xml","form_type":"4"}}]}